23ANDME HOLDING CO.

(ME)
  Report
Real-time Estimate Cboe BZX  -  05/26 02:25:47 pm EDT
2.965 USD   +2.60%
05/1223andMe to Report FY2022 Fourth Quarter and Full Year Financial Results
GL
05/1223andMe to Report FY2022 Fourth Quarter and Full Year Financial Results
AQ
04/1323ANDME : Current Report (Form 8-K)
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

23andMe : to buy telehealth firm Lemonaid for $400 mln

10/22/2021 | 07:32am EDT
Attendees visit the 23andMe booth at the RootsTech annual genealogical event in Salt Lake City

Oct 22 (Reuters) - Direct-to-consumer DNA testing firm 23andMe Holding Co said on Friday it would buy privately held company Lemonaid Health Inc for $400 million in a cash-and-stock deal, as it looks to expand into telemedicine.

Lemonaid Health offers patients direct online access for a number of common conditions, from consultation through treatment. It also offers free and fast delivery of prescription medications.

"By starting with genetics as the foundation, we will give patients and healthcare providers better information about health risks and treatment," 23andMe Chief Executive Officer Anne Wojcicki said in a statement.

Sunnyvale, California-based 23andMe is known for its genetic ancestry tests but also aims to develop treatments for diseases such as cancer and respiratory disorders.

The company said it would pay 25% of the total deal value in cash and the rest in shares.

The deal is expected to close by the end of 2021.

23andMe went public in February through a blank-check firm, backed by Virgin Group founder Sir Richard Branson, in a deal that valued the merged entity at $3.5 billion. (Reporting by Dania Nadeem in Bengaluru; Editing by Sriraj Kalluvila)


© Reuters 2021
All news about 23ANDME HOLDING CO.
05/1223andMe to Report FY2022 Fourth Quarter and Full Year Financial Results
GL
05/1223andMe to Report FY2022 Fourth Quarter and Full Year Financial Results
AQ
04/1323ANDME : Current Report (Form 8-K)
PU
04/1323ANDME HOLDING CO. : Shareholder Director Nominations, Other Events (form 8-K)
AQ
04/04Sequoia Capital promotes Roelof Botha to senior steward
RE
03/2023ANDME HOLDING CO.(NASDAQGS : ME) added to S&P Health Care Services Select Industry Index
CI
03/1723ANDME HOLDING CO.(NASDAQGS : ME) added to S&P Health Care Services Select Industry Index
CI
03/1623ANDME HOLDING CO.(NASDAQGS : ME) added to S&P Health Care Services Select Industry Index
CI
03/1523ANDME HOLDING CO.(NASDAQGS : ME) added to S&P Health Care Services Select Industry Index
CI
03/1523andMe to Present at American Association for Cancer Research (AACR) 2022 Annual Meeti..
GL
More news
Analyst Recommendations on 23ANDME HOLDING CO.
More recommendations
Financials (USD)
Sales 2022 275 M - -
Net income 2022 -250 M - -
Net cash 2022 556 M - -
P/E ratio 2022 -4,13x
Yield 2022 -
Capitalization 1 292 M 1 292 M -
EV / Sales 2022 2,67x
EV / Sales 2023 3,00x
Nbr of Employees 500
Free-Float 74,7%
Chart 23ANDME HOLDING CO.
Duration : Period :
23andMe Holding Co. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends 23ANDME HOLDING CO.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 2,89 $
Average target price 8,43 $
Spread / Average Target 192%
EPS Revisions
Managers and Directors
Anne E. Wojcicki Chief Executive Officer & Director
Steven J. Schoch Chief Financial & Accounting Officer
Steve Lemon Vice President-Engineering
Joyce Tung Vice President-Research
L. Okey Onyejekwe VP-Healthcare Operations & Medical Affairs
Sector and Competitors